572 related articles for article (PubMed ID: 34158626)
21. Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment.
Rosewell Shaw A; Suzuki M
Front Immunol; 2018; 9():2103. PubMed ID: 30298067
[TBL] [Abstract][Full Text] [Related]
22. A promising future in cancer immunotherapy: Oncolytic viruses.
Seyed-Khorrami SM; Azadi A; Rastegarvand N; Habibian A; Soleimanjahi H; Łos MJ
Eur J Pharmacol; 2023 Dec; 960():176063. PubMed ID: 37797673
[TBL] [Abstract][Full Text] [Related]
23. Oncolytic Viruses: Priming Time for Cancer Immunotherapy.
Russell L; Peng KW; Russell SJ; Diaz RM
BioDrugs; 2019 Oct; 33(5):485-501. PubMed ID: 31321623
[TBL] [Abstract][Full Text] [Related]
24. Application of oncolytic virus in tumor therapy.
Huang Z; Guo H; Lin L; Li S; Yang Y; Han Y; Huang W; Yang J
J Med Virol; 2023 Apr; 95(4):e28729. PubMed ID: 37185868
[TBL] [Abstract][Full Text] [Related]
25. Oncolytic virotherapy as promising immunotherapy against cancer: mechanisms of resistance to oncolytic viruses.
Goradel NH; Alizadeh A; Hosseinzadeh S; Taghipour M; Ghesmati Z; Arashkia A; Negahdari B
Future Oncol; 2022 Jan; 18(2):245-259. PubMed ID: 34821517
[TBL] [Abstract][Full Text] [Related]
26. Arming oncolytic viruses with bispecific T cell engagers: The evolution and current status.
Wang Y; Cheng P
Biochim Biophys Acta Mol Basis Dis; 2024 Feb; 1870(2):166962. PubMed ID: 37984801
[TBL] [Abstract][Full Text] [Related]
27. Interleukin-7-loaded oncolytic adenovirus improves CAR-T cell therapy for glioblastoma.
Huang J; Zheng M; Zhang Z; Tang X; Chen Y; Peng A; Peng X; Tong A; Zhou L
Cancer Immunol Immunother; 2021 Sep; 70(9):2453-2465. PubMed ID: 33543339
[TBL] [Abstract][Full Text] [Related]
28. Synergistic combination of oncolytic virotherapy with CAR T-cell therapy.
Ajina A; Maher J
Prog Mol Biol Transl Sci; 2019; 164():217-292. PubMed ID: 31383406
[TBL] [Abstract][Full Text] [Related]
29. Adenovirus-mediated specific tumor tagging facilitates CAR-T therapy against antigen-mismatched solid tumors.
Tang X; Li Y; Ma J; Wang X; Zhao W; Hossain MA; Yang Y
Cancer Lett; 2020 Sep; 487():1-9. PubMed ID: 32454143
[TBL] [Abstract][Full Text] [Related]
30. Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity.
McKenna MK; Englisch A; Brenner B; Smith T; Hoyos V; Suzuki M; Brenner MK
Mol Ther; 2021 May; 29(5):1808-1820. PubMed ID: 33571680
[TBL] [Abstract][Full Text] [Related]
31. Development of oncolytic virotherapy: from genetic modification to combination therapy.
Lan Q; Xia S; Wang Q; Xu W; Huang H; Jiang S; Lu L
Front Med; 2020 Apr; 14(2):160-184. PubMed ID: 32146606
[TBL] [Abstract][Full Text] [Related]
32. Overview of the pre-clinical and clinical studies about the use of CAR-T cell therapy of cancer combined with oncolytic viruses.
Zarezadeh Mehrabadi A; Roozbahani F; Ranjbar R; Farzanehpour M; Shahriary A; Dorostkar R; Esmaeili Gouvarchin Ghaleh H
World J Surg Oncol; 2022 Jan; 20(1):16. PubMed ID: 35027068
[TBL] [Abstract][Full Text] [Related]
33. Multidirectional Strategies for Targeted Delivery of Oncolytic Viruses by Tumor Infiltrating Immune Cells.
Osali A; Zhiani M; Ghaebi M; Meymanat M; Esmaeilzadeh A
Pharmacol Res; 2020 Nov; 161():105094. PubMed ID: 32795509
[TBL] [Abstract][Full Text] [Related]
34. Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors.
Porter CE; Rosewell Shaw A; Jung Y; Yip T; Castro PD; Sandulache VC; Sikora A; Gottschalk S; Ittman MM; Brenner MK; Suzuki M
Mol Ther; 2020 May; 28(5):1251-1262. PubMed ID: 32145203
[TBL] [Abstract][Full Text] [Related]
35. Using Oncolytic Virus to Retask CD19-Chimeric Antigen Receptor T Cells for Treatment of Pancreatic Cancer: Toward a Universal Chimeric Antigen Receptor T-Cell Strategy for Solid Tumor.
Chen C; Park AK; Monroy I; Ren Y; Kim SI; Chaurasiya S; Priceman SJ; Fong Y
J Am Coll Surg; 2024 Apr; 238(4):436-447. PubMed ID: 38214445
[TBL] [Abstract][Full Text] [Related]
36. Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia.
Wang W; Liu S; Dai P; Yang N; Wang Y; Giese RA; Merghoub T; Wolchok J; Deng L
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34593618
[TBL] [Abstract][Full Text] [Related]
37. Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas.
Zeng J; Li X; Sander M; Zhang H; Yan G; Lin Y
Front Immunol; 2021; 12():721830. PubMed ID: 34675919
[TBL] [Abstract][Full Text] [Related]
38. Oncolytic Virotherapy: A New Paradigm in Cancer Immunotherapy.
Volovat SR; Scripcariu DV; Vasilache IA; Stolniceanu CR; Volovat C; Augustin IG; Volovat CC; Ostafe MR; Andreea-Voichița SG; Bejusca-Vieriu T; Lungulescu CV; Sur D; Boboc D
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256250
[TBL] [Abstract][Full Text] [Related]
39. Oncolytic viruses-immunotherapeutics on the rise.
Keller BA; Bell JC
J Mol Med (Berl); 2016 Sep; 94(9):979-91. PubMed ID: 27492706
[TBL] [Abstract][Full Text] [Related]
40. Programming CAR T cells to enhance anti-tumor efficacy through remodeling of the immune system.
Wang X; Wu Z; Qiu W; Chen P; Xu X; Han W
Front Med; 2020 Dec; 14(6):726-745. PubMed ID: 32794014
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]